For hormone receptor-positive Invasive Ductal Carcinoma (IDC), the treatment often involves hormone therapy to block the effects of hormones that the cancer cells rely on to grow. Here are some common approaches:

1. **Tamoxifen**: This medication attaches to the hormone receptors on the cancer cells, preventing the body's Show Full Answer

For hormone receptor-positive Invasive Ductal Carcinoma (IDC), the treatment often involves hormone therapy to block the effects of hormones that the cancer cells rely on to grow. Here are some common approaches:

1. **Tamoxifen**: This medication attaches to the hormone receptors on the cancer cells, preventing the body's natural hormones (like estrogen and progesterone) from stimulating cancer growth.

2. **Aromatase Inhibitors**: These are typically used in postmenopausal women and work by reducing the amount of estrogen the body makes, which can help slow or stop the growth of hormone receptor-positive breast cancer cells.

These treatments can be crucial in managing hormone receptor-positive IDC, potentially alongside other therapies depending on the stage and specific characteristics of the cancer.

 This AI-generated response comes from MyBCTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Invasive Ductal Carcinoma (IDC): Your Guide | MyBCTeam

6 HER2-Positive Breast Cancer Treatments: Chemotherapy and More | MyBCTeam